GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » Earnings Yield (Joel Greenblatt) %

MBRX (Moleculin Biotech) Earnings Yield (Joel Greenblatt) % : -1,428.57% (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Earnings Yield (Joel Greenblatt) %?

Moleculin Biotech's Enterprise Value for the quarter that ended in Dec. 2024 was $1.94 Mil. Moleculin Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-26.64 Mil. Moleculin Biotech's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2024 was -1,428.57%.

The historical rank and industry rank for Moleculin Biotech's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

MBRX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -243.9   Med: 0   Max: 0
Current: -232.56

MBRX's Earnings Yield (Joel Greenblatt) % is ranked worse than
93.59% of 1310 companies
in the Biotechnology industry
Industry Median: -12.375 vs MBRX: -232.56

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Moleculin Biotech's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Moleculin Biotech Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Moleculin Biotech's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Earnings Yield (Joel Greenblatt) % Chart

Moleculin Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.02 129.87 250.00 -526.32 -1,428.57

Moleculin Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -526.32 1,111.11 2,000.00 No Debt -1,428.57

Competitive Comparison of Moleculin Biotech's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Moleculin Biotech's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moleculin Biotech's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's Earnings Yield (Joel Greenblatt) % falls into.


;
;

Moleculin Biotech Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Moleculin Biotechs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2024 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-26.641/1.9443
=-1,370.21 %

Moleculin Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.64 Mil.



Moleculin Biotech  (NAS:MBRX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Moleculin Biotech Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Moleculin Biotech Business Description

Industry
Traded in Other Exchanges
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Executives
Jonathan P. Foster officer: Exec. Vice President and CFO 2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp director, 10 percent owner, officer: Chairman and Acting CEO 1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco director PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker 10 percent owner, officer: President and COO
Michael D Cannon director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth officer: Chief Financial Officer 2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380